MJFF encourages data scientists to use open-access information from the Parkinson’s Progression Markers Initiative to answer one of the following questions:
- What factors at baseline predict clinical progression of Parkinson’s?
- What are sub-types of Parkinson’s disease?
PPMI is a longitudinal, observational study sponsored by MJFF that launched in 2000. The dataset contains clinical, molecular and imaging data for nearly 1,000 participants including people with early-stage Parkinson’s, individuals with clinical risk factors, carriers of genetic mutations associated with the disease and control volunteers.
The study is supported by 17 industry partners, including GE Healthcare, which will provide one of the $25,000 grants. MJFF will provide the other grant.
Submissions, due September 7, will be judged on methodology, predictive accuracy of statistical models and algorithms, along with impact, relevancy and usability in Parkinson’s research.
Winners will be named in November.
More articles on supply chain:
6 things to know about international cancer drug costs
Patient trials deem wearable artificial kidney viable prototype
Fentanyl: 7 things to know about the drug that killed Prince
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
